文献速递肺外科

肺切除与寡转移肺癌长期生存相关,应保留为治疗选择

Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-03-25

该单中心回顾性研究纳入2000-2017年88例cT1-3N0-2M1非小细胞肺癌、≤3个同步转移且体能状态0-1、接受全面局部巩固治疗的患者,按原发灶治疗方式分析。手术组25例中位生存55.2个月,放疗组63例23.4个月;两组局部区域失败与系统进展无差异。结论认为肺切除可行且与长期生存相关,应保留为可手术寡转移患者的局部巩固治疗选项。

要点

  • 手术组中位生存55.2个月,5年总生存48.0%;放疗组分别为23.4个月和24.2%。

核心结论

  • 肺切除在选择的同步寡转移非小细胞肺癌患者中可行,并与长期生存相关。
  • 手术应继续作为可手术寡转移非小细胞肺癌患者纳入随机临床试验的局部巩固治疗选项。

研究设计与样本

  • 单中心回顾性分析,2000-2017年,纳入cT1-3N0-2M1非小细胞肺癌、≤3个同步转移、体能状态0-1且接受全面局部巩固治疗的患者。
  • 共88例,按原发灶局部巩固治疗方式分为放疗组63例(71.6%)和手术组25例(28.4%)。
  • 手术组中肺叶切除20/25(80.0%)、全肺切除3/25(12.0%)、亚肺叶切除2/25(8.0%)。

主要发现

  • 手术组中位术后生存55.2个月(95%CI 20.1至未达到),1年和5年总生存分别为95.7%和48.0%。
  • 放疗组中位术后生存23.4个月(95%CI 17.2-35.9),1年和5年总生存分别为74.3%和24.2%。
  • 手术组患者更年轻且胸腔内疾病负荷更低;从诊断到原发灶局部巩固治疗的时间两组相似。

关键数值与推荐

  • 纳入标准:cT1-3N0-2M1非小细胞肺癌、≤3个同步转移、体能状态0-1、接受全面局部巩固治疗。

临床怎么用

  • 对可手术的同步寡转移非小细胞肺癌患者,肺切除可作为局部巩固治疗选项之一。
  • 治疗决策需结合年龄和胸腔内疾病负荷等选择因素,并应支持患者纳入 ongoing 和未来随机临床试验。

局限性

  • 单中心回顾性设计,样本量88例,手术组仅25例。
  • 手术组与放疗组在年龄和胸腔内疾病负荷上存在差异,可能存在选择偏倚。
  • 原文未报告倾向评分匹配或 multivariable 校正分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Comprehensive local consolidative therapy led to improved overall survival in oligometastatic non-small cell lung cancer in a recent phase II trial, yet the role of pulmonary resection in ongoing oligometastatic trials is a matter of controversy. We sought to examine outcomes after pulmonary resection with radiotherapy used as a benchmark comparator. METHODS: Patients treated at a single institution (2000-2017) with cT1-3N0-2M1 non-small cell lung cancer, 3 or less synchronous metastases, and performance status 0 to 1, and who received comprehensive local consolidative therapy were analyzed according to local consolidative therapy modality for the primary lesion. Progression was analyzed with death as a competing risk. RESULTS: Of 88 patients meeting inclusion criteria, 63 (71.6%) received radiotherapy for local consolidative therapy modality for the primary lesion and 25 (28.4%) underwent surgery (lobectomy 20/25 [80.0%], pneumonectomy 3/25 [12.0%], sublobar 2/25 [8.0%]). Time from diagnosis to local consolidative therapy modality for the primary lesion was similar. Surgical patients were younger and had lower intrathoracic disease burden. Ninety-day post-treatment mortality was low (surgery 0/25 [0.0%], radiotherapy 1/63 [1.6%]). Median postoperative survival time was 55.2 months (95% confidence interval, 20.1 to not reached), with 1- and 5-year overall survivals of 95.7% and 48.0%, respectively. After radiotherapy, median postoperative survival time was 23.4 months (confidence interval, 17.2-35.9); 1- and 5-year overall survivals were 74.3% and 24.2%, respectively. No differences were observed between modalities in site of first failure, cumulative incidence of locoregional failure (P = .635), or systemic progression (P = .747). CONCLUSIONS: Pulmonary resection is feasible and associated with long-term survival in selected patients with synchronous oligometastatic non-small cell lung cancer. Surgery should remain a local consolidative therapeutic option for patients with operable oligometastatic non-small cell lung cancer enrolled in ongoing and future randomized clinical trials.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mitchell KG, Farooqi A, Ludmir EB, et al. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. J Thorac Cardiovasc Surg. 2020. PMID: 32331820. doi:10.1016/j.jtcvs.2020.02.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。